Decent Newsroom
Sign In

Bromantane: Mechanism, Dosing & the Future

By Nootopics July 3, 2026

Research and education, not medical advice.

This page compiles my own research posts on Bromantane into one organized reference. Everything regarding mechanism is purely theoretical, but I think it’s the single most convincing theory on Bromantane’s dopamine sensitization, and how it’s able to do what it does. A lot of this probably won’t make sense to you if you’re a beginner. For background on the broader system, see Dopamine.

Mechanism

It appears that Bromantane is not only structurally, but functionally similar to Amantadine, and so it’s plausible Bromantane may act through the same mechanism (but stronger). Bromantane shows much more pronounced dopaminergic activity, it’s a more recent analog of Amantadine.

First off, it’s good we establish what Medium Spiny Neurons (MSNs) are. The indirect type contain D2-type receptors, whereas the direct type contain D1-type, except for the mixed subpopulation found primarily in the nucleus accumbens shell. These mixed type MSNs explain why D2 activation upregulates Tyrosine Hydroxylase there, whereas D2 activation everywhere else is inhibitory. https://en.wikipedia.org/wiki/Medium_spiny_neuron ELI5 of MSNs: direct MSNs encourage inappropriate body movements (impulse/ optimism), whereas indirect MSNs discourage it (rationality/ pessimism).

It appears that L-Dopa causes dyskinesia through biasdly enhancing expression of direct MSNs (via increased striatum BDNF and thus D1/ D3 hyperactivation) while impairing indirect MSNs (D2) during its effect. This is why inappropriate movements can be observed during its effect, while worsened loss of movement can be observed after its effect. Amantadine not only improves dyskinesia during L-Dopa, it decreases the perceived withdrawal, essentially: https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd181565

Kir2.1 channel blockade

Unlike previously thought, Amantadine’s primary mechanism is not NMDA antagonism and, like Bromantane, the higher doses do not accurately represent the activity of these drugs in what is commonly used. Ironically it’s been elucidated that Amantadine is actually an Inwardly Rectifying Kir2 (potassium channel) blocker, which enhances NMDA expression in MSNs, influencing LTP in indirect MSNs and allowing activation in the presence of elevated dopamine: https://www.jci.org/articles/view/133398 . Furthermore, this is evidenced by enhanced MSN response to dopamine, at the expense of D2 receptor density, in rodents treated with Amantadine: https://sci-hub.se/https://www.sciencedirect.com/science/article/abs/pii/S000689930202961X?via%3Dihub

I want to make it clear that my theory on Bromantane being a kir2.1 potassium channel inhibitor is just that - a theory. But there are many things to support this theory. Bromantane decreases the noise to signal ratio in preclinical studies, and can reduce work errors, oppositely to the stimulant compound they used which acts as a dopamine reuptake inhibitor. This goes back to the fact that indirect medium spiny neurons (iMSNs, D2 receptor containing) are inhibited in the presence of higher dopamine, resulting in less neuroplasticity and less calculated decisions. iMSNs are a class of GABAergic neurons which finely tune behavior and movement. This is why dyskinesia and psychosis develops in Parkinson’s patients given L-Dopa, and why Amantadine prevents it. Amantadine both decreases ON time (dyskinesia) and OFF time (withdrawal) of levodopa, which is only possible by inhibiting Kir2.1, as it increases C-Fos in iMSN neurons which as a result resensitizes D2 receptors.

The argument has been made that Kir2.1 potassium channel inhibition isn’t responsible for the therapeutic effects of Amantadine, but I thoroughly disagree. Their reasoning was that ~29uM is too high to inhibit Kir2.1, as plasma concentrations are much lower, however brain tissue was found to contain 48.2-386 uM in post-mortem subjects. Additionally, Kir2.1 can be inhibited intracellularly, and a significant amount of Amantadine concentrates in the cytosol, and not just in the lysosomes. Thus the original paper on Amantadine stands, and I stick by my predictions on Bromantane.

Cytokines, HDAC inhibition, and neurotrophins

So where does the sensitization come from? Well, Bromantane, like Amantadine, increases neurotrophic factors such as BDNF and NGF: https://sci-hub.se/https://link.springer.com/article/10.1007%2Fs10517-012-1516-z . It appears that through a reduction in inflammatory cytokines, which is shown in both Amantadine and Bromantane, there is a decrease in the activity of histone deacetylases, thus enhancing the expression of BDNF (and GDNF in Amantadine’s case, likely for Bromantane as well but unconfirmed), increasing the activity of C-Fos, and restoring sensitivity to dopamine receptors: https://www.frontiersin.org/articles/10.3389/fnagi.2020.605330/full . C-Fos is used as a common marker to demonstrate stimulant-induced tolerance. This explains the histone deacetylase inhibition seen with Bromantane, and what role it may play.

Additionally, Kir2.1 potassium channel inhibition reduces inflammatory cytokines, and as a result, HDAC is indirectly inhibited, which gives rise to neurotrophic growth factors. This is seen with both Amantadine and Bromantane. This is believed to be the primary mechanism for both compounds when it comes to dopaminergic sensitivity.

Indirect MSN balance, CREB and D1

So how does Bromantane work? Theoretically, Bromantane balances the expression of Medium Spiny Neurons and enhances the sensitivity of dopamine receptors in the striatum with neurotrophins. Some inhibitory cells are still “turned on”, distributing downregulation in a way that prevents dysregulation. This means that the response of the central nervous system is not only intensified, but modified to nullify perceivable withdrawal, addiction, and dyskinesia. Bromantane truly is “enhancing”.

The increased availability of indirect MSNs during higher dopamine explains why stimulation is less pronounced then but significant in high stress environments, as CREB is triggered and D1 expression is increased, working to create a synergy. The enhancement of CREB and Tyrosine Hydroxylase by neurotrophins is weaker than the enhancement provoked by D1 activation, but when both occur at the same time the resulting dopaminergic effects are amplified. An inwardly Rectifying Kir2 blockade and decrease of inflammatory cytokines would not only fully explain Bromantane’s effects, it would explain the CREB enhancement responsible for its dopamine enhancement: Calcium influx (likely downstream of indirect NMDA enhancement from Kir2 blockade), RAS (neurotrophins) and PKA (adenylate cyclase cAMP accumulation from D1 stimulation). In complete alignment with what can be observed with Amantadine.

Does it upregulate dopamine?

Yes, this much is proven. Enhanced locomotion (key marker for dopaminergic activity in studies) was displayed up to two months after Bromantane cessation in preclinical studies, and one month in people. I found a study in which Amantadine upregulated dopamine receptors, but I won’t include it. The reasoning for this, besides the fact that some studies say the opposite, is people should stop focusing on receptor density when it comes to enhanced dopaminergic response. Increased or decreased receptor density is superficial, and increased dopamine receptor density can be found among most dopaminergics, including meth. To my knowledge only Bromantane, ALCAR and GDNF have been shown to produce lasting dopaminergic effects after discontinuation, with the former two also increasing GDNF downstream of HDAC.

Pharmacokinetics & route

I give my apologies, as I have re-read the Russian book on adamantanes, and it would appear there has either been a mistranslation or typo by the Russian authors which wrongly made me believe its half life was increased when administered intravenously. Looking at the data table, it would appear the plasma half life is reduced when injected. However, this does not mean that intranasal Bromantane isn’t a superior route of administration. It has a wide volume of distribution, which results in less access to upper regions of the body, such as the brain due to lower organ accumulation (i.e. the liver and heart).

In isolation, the half life of Bromantane in the brain is 7 hours. When Bromantane is taken orally, it is only detected in the plasma of subjects for about 4 hours. The metabolites of Bromantane, downstream of cytochrome P450, are anticholinergic, with a reduced stimulant profile. This could explain the widespread phenomenon of weaker effects when using oral Bromantane.

Bromantane has never been used intranasally in studies, but we can reference other things. There is a study on actoprotectors claiming its oral bioavailability is 42% but after thorough investigation, I have found there is no evidence to back this up. Anecdotally, we see that oral always fails and sublingual takes up to 30 minutes. This means another route of administration is more desirable. Amantadine, Bromantane predecessor, has been investigated for intranasal use in previous studies: https://pubmed.ncbi.nlm.nih.gov/26886345/ Furthermore, our results have indicated the potential for nose-to-brain delivery of Amantadine, yielding a potentially novel avenue therapeutics delivery route to avoid the blood brain barrier.

Dosing & the nasal spray

Recently I have developed the Bromantane nasal spray, an invention that utilizes a high concentration Bromantane with Caprylic acid, a medium-chain fatty acid that, unlike long-chain fatty acids, does not pose a threat for Lipoid Pnemonia. This allows it to be used as a solvent for intranasal use. Additionally, it is anti-bacterial, anti-fungal and anti-viral, so rest assured it is sterile. Since Caprylic acid is lubricating, it won’t dry your nose out, therefore it’s better than snorting the powder and there’s less risk for nasal membrane damage, which could still be an issue despite Bromantane’s non-toxic nature. Yes it’s soluble in caprylic acid. No other solvent necessary.

Caprylic acid, referenced here as Octanoic acid, is perfectly absorbed intranasally, where there is then a direct route to the brain through the nasal cavity. Since it is a small fatty acid, and Bromantane is lipophilic in nature, this perfects the absorption of Bromantane and allows it easy transport to the brain, where there is then far greater effect. Essentially, Bromantane is perfect for intranasal use, and this explains why it works so well intranasally.

On dosing: 9mg per spray, 180 sprays. No man. You really only need 2 sprays per day. It’s a lot more potent this route. The quantity loses its value simply due to the labor involved with making something like it and the fact that it still works (even better) at the lower dose. Should be about twice as strong per mg intranasally as well as with faster onset. Easier to use, easier on the nasal membranes and honestly I feel like the spray is more potent.

A note on alternative solvents and routes: I haven’t researched capric acid so I’d advise against it until further research has been done. Snorting the powder won’t work as good and it’s bad for your nasal membranes especially if it’s not a milled powder. Someone who can read Russian told me the original Ladasten was sold in a cyclodextrin complex, not sure how true that is. We tried to replicate this and it failed.

Safety

Recently a user has proposed that Bromantane may inhibit hERG, which has been identified as a toxic mechanism by a wide variety of drugs. However this just isn’t the case. They were basing it off of predictive analysis which, unlike some other AI, is still in the dark ages. As some others mentioned, various other prescription drugs are falsely flagged as hERG blockers, including long studied drugs such as Prozac, Propanolol and Clonazepam.

Bromantane’s LD50 is 8100mg/kg in mice, which is a lot. That would make the lethal dose in humans something like 40 grams.

And finally, to dispel this rumor for good, Bromantane can act oppositely to an hERG blocker. Bromantane increases blood pumping to the left ventricle and heart beating (as shown by minute and stroke volume) which is opposite to hERG blockade. Bromantane is part of a class of drugs called antihypoxiants, and hypoxia inhibits hERG.

On cardiovascular safety, the clinical data on Ladasten: The data obtained indicate a high level of safety, efficacy and good tolerability of Ladasten in the treatment of asthenia and asthenic spectrum disorders (somatogenic asthenia, nosogenes), the formation of which is associated with widespread cardiovascular pathology. Taking into account the high compliance of patients and the convenience of oral administration, we can recommend Ladasten for use in the treatment of asthenia in patients with cardiovascular diseases. Bromantane has numerous clinical studies conducted in Russian patients, in which low (or no) side effects were consistent among all.

Bromantane is partially anxiolytic, so if it makes you anxious you would be an anomaly in this case, though everyone’s different of course.

Depression & immune

Bromantane was basically created for the Russian version of CFS, and although it has some immunosuppressant effects, there are immunostimulant effects as well, as evidenced by increased T-cell synthesis.

The social-defeat-stress study abstract: “The aim of the present study was to investigate the effects of the anti-asthenic drug ladasten on behavioral patterns and T-cell subsets in blood, spleen, and thymus in socially stressed male C57Bl/6 mice. Mice subjected to social defeat stress (SDS) for 25 days developed a depressive-like phenotype. The submissive SDS animals were assigned to one of two treatment groups: one group was treated with ladasten (30 mg/kg, i.p.) for up to 5 days, and the other one was administered vehicle as a control. Twenty four hours after the last injection, behavioral parameters were tested, and trunk blood and tissue samples were collected. SDS mice from the vehicle-treated group showed a subordinate and passive avoidance behavior with significantly decreased spontaneous locomotor activity (SLA) and exhibited impaired parameters in the forced swimming test (FST). Changes in behavioral status were correlated with an increase spleen weight, a decrease in thymic index and a shift in the CD4/CD8 balance toward T-cytotoxic cells. The behavior parameters were reversed in the group treated with ladasten compared to the untreated SDS group and were similar to those of unstressed mice. Treatment of socially stressed mice with ladasten normalized the amount of T-lymphocyte cells in the blood, spleen, and thymus. These findings support the notion that depression is accompanied by cell-mediated immune activation and that targeting this pathway may be a new therapeutic approach for treatment. Furthermore, our data support further investigations of ladasten as a potent anti-depressive drug which can be used alone as well as in combination with other anti-depressants.”

For an 80kg person the 30 mg/kg dose used in that study would translate to roughly 192mg, per the dose conversion guide: https://www.researchgate.net/profile/Salah-Adlat/post/How_to_convert_human_dose_to_animal_dose/attachment/60f29ed2647f3906fc898bcf/AS%3A1046485969932289%401626513106399/download/A+simple+practice+guide+for+dose+conversion+between+animals+and+human.pdf

On stacking for dopaminergic ends: sulbutiamine decreases dopamine. Don’t think that’s what you want.

The future

Bromantane is being investigated by Johnson & Johnson, AbbVie, and Merck (pharmaceutical companies) for the treatment of Parkinson’s. Because of this, eventually Bromantane will become prescribed and perhaps more tightly regulated in the US. Funny, I was convinced that Bromantane stabilized in Tetraether Bipolar Lipid Membranes (to make it water soluble) would be a viable OTC medication. Seems that road is blocked.

I am looking into Bromantane analogues, and may be able to get some basic studies conducted on them to measure safety. This is probably the “future” of this compound.

On vendors: I don’t like the people at science.bio. Low morals and ridiculously high prices. Selling and popularizing kratom, getting people addicted to shit they’d probably otherwise ignore on a shop publicly thought to be for nootropics. Overcharging customers. And when shops like that get shut down, they just pop up under a new name like before.

Sources

Write a comment